Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTR5A | P47898 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8564068 | 1.00 | NISCH (0.46) | NISCHHPGDBRD4CREBBPPARP1 | |
| SCHEMBL8564064 | 1.00 | NISCH (0.46) | NISCHHPGDBRD4CREBBPPARP1 | |
| SCHEMBL2936539 | 0.84 | HPGD (0.47) | NISCHHPGDBRD4CREBBPPARP1 | |
| SCHEMBL19392968 | 0.77 | BRD4 (0.54) | NISCHHPGDBRD4CREBBPPARP1 | |
| SCHEMBL517074 | 0.77 | BRD4 (0.54) | NISCHHPGDBRD4CREBBPPARP1 | |
| SCHEMBL15158184 | 0.74 | HPGD (0.48) | NISCHHPGDBRD4CREBBPPARP1 | |
| SCHEMBL1190290 | 0.74 | OTUD7B (0.36) | NISCH | |
| SCHEMBL15718086 | 0.73 | NISCH (0.49) | NISCHHPGDBRD4CREBBPPARP1 | |
| SCHEMBL214287 | 0.73 | NISCH (0.49) | NISCHHPGDBRD4CREBBPPARP1 | |
| SCHEMBL3966534 | 0.73 | NISCH (0.49) | NISCHHPGDBRD4CREBBPPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2917194-B1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | LILLY CO ELI (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2917194-B1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | LILLY CO ELI (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9416138-B2 | Benzyl sulfonamide compounds useful as MoGAT-2 inhibitors | ELI LILLY AND COMPANY (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416138-B2 | Benzyl sulfonamide compounds useful as MoGAT-2 inhibitors | ELI LILLY AND COMPANY (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416138-B2 | Benzyl sulfonamide compounds useful as MoGAT-2 inhibitors | ELI LILLY AND COMPANY (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150284404-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY | 2015-10-08 | — | — | US | disclosed |
| US-20150284404-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY | 2015-10-08 | — | — | US | disclosed |
| US-20150284404-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY | 2015-10-08 | — | — | US | disclosed |
| EP-2917194-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | Eli Lilly and Company (US) | 2015-09-16 | — | — | EP | disclosed |
| WO-2014074365-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2014-05-15 | — | — | WO | disclosed |
| WO-2014074365-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2014-05-15 | — | — | WO | disclosed |
| US-8440691-B2 | Tetrahydroquinolinyl compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBVIE INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2527339-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | Abbott Laboratories (US) | 2012-11-28 | — | — | EP | disclosed |
| US-20110152250-A1 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-7812019-B2 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBOTT LABORATORIES (US) | 2010-10-12 | — | — | US | disclosed |
| US-20060128689-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| US-6699695-B1 | FOR EXAMPLE, CONVERTING 2-HYDROXY-4-METHYLTHIOBUTYRONITRILE INTO THE CORRESPONDING AMIDE, WHICH IS A PRECURSOR TO THE FEED SUPPLEMENT 2-HYDROXY-4-METHYLTHIOBUTYRIC ACID | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2004-03-02 | — | — | US | disclosed |
| EP-1055724-A1 | MICROORGANISMS AND PROCESS FOR PRODUCING AMIDE COMPOUNDS | Daicel Chemical Industries, Ltd. (JP) | 2000-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128689-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | CACNA1E, CACNA1D, CACNA1S | NISCH 1646/4885HPGD 3370/4885BRD4 3228/4885 |
| US-20150284404-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | MOGAT2, SOAT1, SOAT2 | NISCH 3375/4885HPGD 4545/4885BRD4 683/4885 |
| US-20110152250-A1 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | CACNA1E, CACNA1D, CACNA1S | NISCH 1646/4885HPGD 3370/4885BRD4 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.